Nutex Health Inc Financials
Nutex Health Inc (NUTX) reported $875.3M in revenue for fiscal year 2025, up 82.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash-rich, low-capex growth turned a formerly volatile income statement into a self-funding balance-sheet expansion by FY2025.
Cash conversion became the key operating signal: free cash flow of$245.6M was more than triple net income of$70.8M . Minimal reinvestment needs help explain that, because capital spending was just$2.5M even as cash climbed to$185.6M , which makes the business look self-funding rather than balance-sheet constrained as the business scaled.
The margin story is recovery with scale absorption: gross margin rose from
The balance sheet now looks liquid and less debt-led: cash stood at
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nutex Health Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nutex Health Inc has an operating margin of 31.5%, meaning the company retains $31 of operating profit per $100 of revenue. This results in a moderate score of 64/100, indicating healthy but not exceptional operating efficiency. This is up from 27.2% the prior year.
Nutex Health Inc's revenue surged 82.4% year-over-year to $875.3M, reflecting rapid business expansion. This strong growth earns a score of 97/100.
Nutex Health Inc carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.41, Nutex Health Inc holds $3.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 81/100.
Nutex Health Inc converts 28.1% of revenue into free cash flow ($245.6M). This strong cash generation earns a score of 78/100.
Nutex Health Inc earns a strong 21.5% return on equity (ROE), meaning it generates $21 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 65/100. This is down from 39.3% the prior year.
Nutex Health Inc scores 3.56, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nutex Health Inc passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Nutex Health Inc generates $3.51 in operating cash flow ($248.1M OCF vs $70.8M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Nutex Health Inc earns $12.40 in operating income for every $1 of interest expense ($275.6M vs $22.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Nutex Health Inc generated $875.3M in revenue in fiscal year 2025. This represents an increase of 82.4% from the prior year.
Nutex Health Inc's EBITDA was $296.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 97.9% from the prior year.
Nutex Health Inc reported $70.8M in net income in fiscal year 2025. This represents an increase of 35.9% from the prior year.
Nutex Health Inc earned $10.48 per diluted share (EPS) in fiscal year 2025. This represents an increase of 8.2% from the prior year.
Cash & Balance Sheet
Nutex Health Inc generated $245.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 1078.0% from the prior year.
Nutex Health Inc held $185.6M in cash against $29.2M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Nutex Health Inc's gross margin was 50.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 9.9 percentage points from the prior year.
Nutex Health Inc's operating margin was 31.5% in fiscal year 2025, reflecting core business profitability. This is up 4.3 percentage points from the prior year.
Nutex Health Inc's net profit margin was 8.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2.8 percentage points from the prior year.
Nutex Health Inc's ROE was 21.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 17.9 percentage points from the prior year.
Capital Allocation
Nutex Health Inc spent $5.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Nutex Health Inc invested $2.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 9.6% from the prior year.
Not reported for fiscal year 2025.
NUTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $846.7M | $875.3M+82.4% | $479.9M+93.8% | $247.6M+12.9% | $219.3M-33.9% | $331.5M | N/A | $1.4M0.0% | $1.4M+5800.9% | $23K | $0-100.0% | $475K-55.6% | $1.1M-26.9% | $1.5M-8.3% | $1.6M-10.7% | $1.8M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $14.6M | N/A | $830K+63.6% | $508K+1565.4% | $30K | $0-100.0% | $8K-98.3% | $465K-6.2% | $496K-36.7% | $784K+2.5% | $765K |
| Gross Profit | $434.0M | $444.3M+126.4% | $196.3M+464.4% | $34.8M+125.5% | $15.4M-91.4% | $179.3M | N/A | $536K-37.6% | $859K+11847.9% | -$7K | $0-100.0% | $467K-22.7% | $603K-37.5% | $965K+19.1% | $810K-20.5% | $1.0M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | $286K-48.7% | $557K-27.5% | $768K+40.9% | $545K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $60.2M | $51.7M+23.2% | $41.9M+26.2% | $33.2M+67.7% | $19.8M+262.7% | $5.5M | N/A | $3.7M+287.8% | $946K-47.9% | $1.8M+304.3% | $449K-15.8% | $533K-26.3% | $723K-57.3% | $1.7M-29.0% | $2.4M+27.9% | $1.9M |
| Operating Income | $364.3M | $275.6M+110.9% | $130.7M+511.3% | -$31.8M+92.2% | -$406.6M-338.8% | $170.3M | N/A | -$6.9M-720.8% | -$840K+85.2% | -$5.7M-1169.1% | -$449K+15.8% | -$533K+26.3% | -$723K+0.5% | -$727K+53.8% | -$1.6M-86.3% | -$845K |
| Interest Expense | $19.8M | $22.2M+11.5% | $19.9M+22.1% | $16.3M+30.6% | $12.5M+101.6% | $6.2M | N/A | $92K-16.1% | $110K-70.1% | $367K+14144.0% | $3K+182.0% | -$3K+33.3% | -$5K+91.3% | -$55K | N/A | N/A |
| Income Tax | $71.0M | $64.4M+328.9% | $15.0M+396.4% | -$5.1M-138.7% | $13.1M+1255.5% | $966K+432.5% | $181K | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $179.9M | $70.8M+35.9% | $52.1M+213.8% | -$45.8M+89.2% | -$424.8M-420.4% | $132.6M | N/A | -$7.1M-649.0% | -$950K-263.2% | $582K | N/A | $84K+112.2% | -$684K-373.2% | $250K+115.4% | -$1.6M-323.6% | -$383K |
| EPS (Diluted) | — | $10.48+8.2% | $9.69+193.3% | -$10.39 | -$100.36 | $0.22 | $0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NUTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $918.5M+40.2% | $655.3M+64.6% | $398.2M-7.8% | $431.8M+9.4% | $394.7M+232242.5% | $170K-97.5% | $6.7M+1389.1% | $449K-86.5% | $3.3M+551.6% | $511K-93.3% | $7.6M+2620.2% | $281K-73.8% | $1.1M+43.6% | $746K-60.6% | $1.9M |
| Current Assets | $538.8M+84.2% | $292.5M+221.9% | $90.8M-7.3% | $98.0M-36.4% | $154.0M+97963.9% | $157K-87.4% | $1.2M+307.1% | $305K+454.5% | $55K-89.2% | $508K-93.3% | $7.6M+2662.2% | $276K-73.7% | $1.1M+46.6% | $717K-59.2% | $1.8M |
| Cash & Equivalents | $185.6M+356.6% | $40.6M+84.7% | $22.0M-35.8% | $34.3M-5.2% | $36.1M+134014.2% | $27K-97.5% | $1.1M+793.3% | $119K+1162.2% | $9K-10.2% | $11K-91.4% | $122K-3.6% | $127K+372.0% | $27K-74.3% | $105K-53.4% | $225K |
| Inventory | $2.9M+0.6% | $2.9M-15.9% | $3.4M-4.0% | $3.5M+25.6% | $2.8M | $0-100.0% | $27K | $0 | $0 | N/A | $21K | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | $232.4M+296.7% | $58.6M+1.4% | $57.8M-48.7% | $112.8M+616682.3% | $18K-81.8% | $100K-46.2% | $186K+2876.5% | $6K | $0-100.0% | $230K+181.8% | $82K-39.6% | $135K-14.6% | $158K-41.2% | $269K |
| Goodwill | $13.9M0.0% | $13.9M-18.4% | $17.1M+0.3% | $17.0M+1393.1% | $1.1M | $0-100.0% | $3.5M | $0 | N/A | $0-100.0% | $6.7M | N/A | N/A | N/A | $111K |
| Total Liabilities | $495.1M+6.1% | $466.8M+46.3% | $319.1M+2.5% | $311.4M+53.4% | $203.1M+15476.9% | $1.3M-73.0% | $4.8M+148.3% | $1.9M-55.0% | $4.3M-32.2% | $6.4M+5.0% | $6.1M+2030.1% | $285K-44.6% | $515K+17.0% | $440K+52.5% | $289K |
| Current Liabilities | $157.9M+2.4% | $154.2M+164.5% | $58.3M+6.3% | $54.9M+45.6% | $37.7M+3167.1% | $1.2M-75.0% | $4.6M+341.6% | $1.0M+8.8% | $960K-85.0% | $6.4M+5.0% | $6.1M+2030.1% | $285K-44.6% | $515K+17.0% | $440K+52.5% | $289K |
| Long-Term Debt | $29.2M+29.9% | $22.5M-14.6% | $26.3M+14.2% | $23.1M-70.8% | $78.8M | $0 | $0-100.0% | $300K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $329.4M+148.8% | $132.4M+115.5% | $61.5M-35.9% | $95.9M-16.4% | $114.7M+10212.2% | -$1.1M-161.0% | $1.9M+224.1% | -$1.5M-50.2% | -$997K+83.0% | -$5.9M-475.9% | $1.6M+34865.4% | -$4K-100.8% | $556K+81.9% | $306K-80.9% | $1.6M |
| Retained Earnings | -$286.2M+19.8% | -$357.0M+12.7% | -$409.1M-12.6% | -$363.3M-455.1% | $102.3M+661.6% | -$18.2M-45.0% | -$12.6M-130.5% | -$5.5M+43.5% | -$9.6M+5.7% | -$10.2M-265.6% | -$2.8M-198.2% | $2.9M+229.7% | -$2.2M+10.2% | -$2.4M-197.0% | -$824K |
NUTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $279.6M | $248.1M+971.7% | $23.2M+1741.9% | $1.3M-97.5% | $50.6M-70.8% | $173.4M | N/A | -$4.0M-741.7% | -$480K+32.8% | -$715K-160.6% | -$274K-710.6% | $45K-71.8% | $159K+186.9% | -$183K+64.7% | -$519K+21.3% | -$659K |
| Capital Expenditures | $5.5M | $2.5M+9.6% | $2.3M-75.7% | $9.5M-35.1% | $14.6M-60.4% | $36.9M | N/A | $84K | $0 | N/A | N/A | -$2K-11.3% | -$2K | N/A | -$8K-58.4% | -$19K |
| Free Cash Flow | $274.2M | $245.6M+1078.0% | $20.8M+353.0% | -$8.2M-122.9% | $36.0M-73.6% | $136.5M | N/A | -$4.1M-759.2% | -$480K | N/A | N/A | $43K-72.6% | $157K | N/A | -$527K+22.4% | -$679K |
| Investing Cash Flow | -$9.1M | -$5.2M+6.5% | -$5.6M+50.1% | -$11.2M-159.1% | -$4.3M+88.3% | -$37.0M | N/A | -$748K-539.7% | -$117K-5805.6% | $2K+120.5% | -$10K-646.5% | $2K+138.6% | -$5K-363.3% | $2K-99.6% | $418K+1.1% | $413K |
| Financing Cash Flow | -$160.4M | -$97.9M-9077.9% | $1.1M+148.1% | -$2.3M+95.3% | -$48.1M+61.8% | -$125.9M | N/A | $5.7M+714.0% | $705K-1.0% | $712K+312.6% | $172K+436.3% | -$51K+5.9% | -$55K-152.7% | $104K+641.1% | -$19K | N/A |
| Share Buybacks | N/A | $5.0M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NUTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.8%+9.9pp | 40.9%+26.8pp | 14.0%+7.0pp | 7.0%-47.0pp | 54.1% | N/A | 39.2%-23.6pp | 62.9%+94.4pp | -31.6% | N/A | 98.3%+41.9pp | 56.5%-9.6pp | 66.0%+15.2pp | 50.8%-6.3pp | 57.1% |
| Operating Margin | 31.5%+4.3pp | 27.2%+40.1pp | -12.8% | -185.4% | 51.4% | N/A | -504.8% | -61.5% | -24574.5% | N/A | -112.3% | -67.7%-17.9pp | -49.8%+48.9pp | -98.7%-51.4pp | -47.3% |
| Net Margin | 8.1%-2.8pp | 10.8%+29.3pp | -18.5% | -193.7% | 40.0% | N/A | -520.8% | -69.5% | 2512.6% | N/A | 17.7%+81.7pp | -64.0%-81.2pp | 17.1% | -101.9% | -21.5% |
| Return on Equity | 21.5%-17.9pp | 39.3%+113.9pp | -74.5%+368.6pp | -443.1%-558.8pp | 115.7% | N/A | -382.9% | N/A | N/A | N/A | 5.4% | N/A | 45.0%+576.3pp | -531.2%-507.3pp | -23.9% |
| Return on Assets | 7.7%-0.2pp | 8.0%+19.4pp | -11.5%+86.9pp | -98.4%-132.0pp | 33.6% | N/A | -106.3%+105.1pp | -211.4%-228.9pp | 17.5% | N/A | 1.1%+244.8pp | -243.7%-267.1pp | 23.4%+241.1pp | -217.7%-197.4pp | -20.3% |
| Current Ratio | 3.41+1.5x | 1.90+0.3x | 1.56-0.2x | 1.79-2.3x | 4.09+4.0x | 0.14-0.1x | 0.270.0x | 0.29+0.2x | 0.060.0x | 0.08-1.2x | 1.26+0.3x | 0.97-1.1x | 2.04+0.4x | 1.63-4.5x | 6.10 |
| Debt-to-Equity | 0.09-0.1x | 0.17-0.3x | 0.43+0.2x | 0.24-0.4x | 0.69 | N/A | 0.00 | N/A | N/A | N/A | 3.89 | N/A | 0.93-0.5x | 1.44+1.3x | 0.18 |
| FCF Margin | 28.1%+23.7pp | 4.3%+7.7pp | -3.3%-19.7pp | 16.4%-24.8pp | 41.2% | N/A | -301.9% | -35.1% | N/A | N/A | 9.1%-5.6pp | 14.7% | N/A | -33.1%+5.0pp | -38.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Nutex Health Inc Ranks
Frequently Asked Questions
What is Nutex Health Inc's annual revenue?
Nutex Health Inc (NUTX) reported $875.3M in total revenue for fiscal year 2025. This represents a 82.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nutex Health Inc's revenue growing?
Nutex Health Inc (NUTX) revenue grew by 82.4% year-over-year, from $479.9M to $875.3M in fiscal year 2025.
Is Nutex Health Inc profitable?
Yes, Nutex Health Inc (NUTX) reported a net income of $70.8M in fiscal year 2025, with a net profit margin of 8.1%.
What is Nutex Health Inc's EBITDA?
Nutex Health Inc (NUTX) had EBITDA of $296.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Nutex Health Inc have?
As of fiscal year 2025, Nutex Health Inc (NUTX) had $185.6M in cash and equivalents against $29.2M in long-term debt.
What is Nutex Health Inc's gross margin?
Nutex Health Inc (NUTX) had a gross margin of 50.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nutex Health Inc's operating margin?
Nutex Health Inc (NUTX) had an operating margin of 31.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nutex Health Inc's net profit margin?
Nutex Health Inc (NUTX) had a net profit margin of 8.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nutex Health Inc's return on equity (ROE)?
Nutex Health Inc (NUTX) has a return on equity of 21.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nutex Health Inc's free cash flow?
Nutex Health Inc (NUTX) generated $245.6M in free cash flow during fiscal year 2025. This represents a 1078.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nutex Health Inc's operating cash flow?
Nutex Health Inc (NUTX) generated $248.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nutex Health Inc's total assets?
Nutex Health Inc (NUTX) had $918.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nutex Health Inc's capital expenditures?
Nutex Health Inc (NUTX) invested $2.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Nutex Health Inc's current ratio?
Nutex Health Inc (NUTX) had a current ratio of 3.41 as of fiscal year 2025, which is generally considered healthy.
What is Nutex Health Inc's debt-to-equity ratio?
Nutex Health Inc (NUTX) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nutex Health Inc's return on assets (ROA)?
Nutex Health Inc (NUTX) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nutex Health Inc's Altman Z-Score?
Nutex Health Inc (NUTX) has an Altman Z-Score of 3.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nutex Health Inc's Piotroski F-Score?
Nutex Health Inc (NUTX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nutex Health Inc's earnings high quality?
Nutex Health Inc (NUTX) has an earnings quality ratio of 3.51x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nutex Health Inc cover its interest payments?
Nutex Health Inc (NUTX) has an interest coverage ratio of 12.40x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nutex Health Inc?
Nutex Health Inc (NUTX) scores 80 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.